CN103610734B - 一种白花油麻藤提取物在制备治疗白血病药物中的应用 - Google Patents
一种白花油麻藤提取物在制备治疗白血病药物中的应用 Download PDFInfo
- Publication number
- CN103610734B CN103610734B CN201310527764.1A CN201310527764A CN103610734B CN 103610734 B CN103610734 B CN 103610734B CN 201310527764 A CN201310527764 A CN 201310527764A CN 103610734 B CN103610734 B CN 103610734B
- Authority
- CN
- China
- Prior art keywords
- extract
- mucuna birdwoodiana
- tutcher
- mucuna
- extraction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 241001007959 Mucuna birdwoodiana Species 0.000 title claims abstract description 185
- 208000032839 leukemia Diseases 0.000 title claims abstract description 42
- 239000003814 drug Substances 0.000 title claims abstract description 39
- 238000002360 preparation method Methods 0.000 title claims abstract description 26
- 238000003815 supercritical carbon dioxide extraction Methods 0.000 claims abstract description 20
- 239000011347 resin Substances 0.000 claims abstract description 17
- 229920005989 resin Polymers 0.000 claims abstract description 17
- 238000000034 method Methods 0.000 claims abstract description 16
- 239000000203 mixture Substances 0.000 claims abstract description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- 238000000605 extraction Methods 0.000 claims description 63
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 238000001035 drying Methods 0.000 claims description 18
- 239000002904 solvent Substances 0.000 claims description 18
- 239000000341 volatile oil Substances 0.000 claims description 18
- 239000003463 adsorbent Substances 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 12
- 229940079593 drug Drugs 0.000 claims description 11
- 230000001476 alcoholic effect Effects 0.000 claims description 9
- 239000012141 concentrate Substances 0.000 claims description 9
- 239000003480 eluent Substances 0.000 claims description 9
- 239000008187 granular material Substances 0.000 claims description 9
- 230000002879 macerating effect Effects 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 239000002994 raw material Substances 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 23
- 230000000694 effects Effects 0.000 description 11
- 102000014150 Interferons Human genes 0.000 description 6
- 108010050904 Interferons Proteins 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 229940079322 interferon Drugs 0.000 description 6
- 206010008583 Chloroma Diseases 0.000 description 5
- 201000005987 myeloid sarcoma Diseases 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000012980 RPMI-1640 medium Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- -1 and dry Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000684 flow cytometry Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002607 hemopoietic effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 229940127089 cytotoxic agent Drugs 0.000 description 2
- 239000002254 cytotoxic agent Substances 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 210000003714 granulocyte Anatomy 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 229930002330 retinoic acid Natural products 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000008286 Aortic Arch Syndromes Diseases 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- HAVJATCHLFRDHY-UHFFFAOYSA-N Harringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HAVJATCHLFRDHY-UHFFFAOYSA-N 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- YZCKVEUIGOORGS-UHFFFAOYSA-N Hydrogen atom Chemical group [H] YZCKVEUIGOORGS-UHFFFAOYSA-N 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 208000035490 Megakaryoblastic Acute Leukemia Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010058483 Nuchal rigidity Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000001106 Takayasu Arteritis Diseases 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000020700 acute megakaryocytic leukemia Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 208000026915 cervical aortic arch Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 201000009277 hairy cell leukemia Diseases 0.000 description 1
- HAVJATCHLFRDHY-JZTSUELASA-N harringtonine Chemical compound C1=C2CCN3CCC[C@]43C=C(OC)[C@@H](OC(=O)[C@](O)(CCC(C)(C)O)CC(=O)OC)[C@@H]4C2=CC2=C1OCO2 HAVJATCHLFRDHY-JZTSUELASA-N 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- HYFHYPWGAURHIV-UHFFFAOYSA-N homoharringtonine Natural products C1=C2CCN3CCCC43C=C(OC)C(OC(=O)C(O)(CCCC(C)(C)O)CC(=O)OC)C4C2=CC2=C1OCO2 HYFHYPWGAURHIV-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000001595 mastoid Anatomy 0.000 description 1
- 239000002398 materia medica Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 230000003448 neutrophilic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000004197 pelvis Anatomy 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 210000004180 plasmocyte Anatomy 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- MYFATKRONKHHQL-UHFFFAOYSA-N rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C2C=CC(=[NH2+])C=C2OC2=CC(N)=CC=C21 MYFATKRONKHHQL-UHFFFAOYSA-N 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310527764.1A CN103610734B (zh) | 2013-10-31 | 2013-10-31 | 一种白花油麻藤提取物在制备治疗白血病药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310527764.1A CN103610734B (zh) | 2013-10-31 | 2013-10-31 | 一种白花油麻藤提取物在制备治疗白血病药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103610734A CN103610734A (zh) | 2014-03-05 |
CN103610734B true CN103610734B (zh) | 2015-08-12 |
Family
ID=50161468
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310527764.1A Expired - Fee Related CN103610734B (zh) | 2013-10-31 | 2013-10-31 | 一种白花油麻藤提取物在制备治疗白血病药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103610734B (zh) |
-
2013
- 2013-10-31 CN CN201310527764.1A patent/CN103610734B/zh not_active Expired - Fee Related
Non-Patent Citations (2)
Title |
---|
白花油麻藤不同极性部位对60Coγ射线辐射小鼠外周血象的保护作用;王东晓等;《解放军药学学报》;20080415;第24卷(第2期);第103-106页 * |
白花油麻藤化学成分研究;巩婷等;《中国中药杂志》;20100701;第35卷(第13期);第1720-1722页 * |
Also Published As
Publication number | Publication date |
---|---|
CN103610734A (zh) | 2014-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103768534A (zh) | 一种具有抗肿瘤活性的中药组合物 | |
WO2023065376A1 (zh) | 一种包含落新妇苷和/或其异构体的组合物在制备治疗银屑病的药物中的用途 | |
CN103585227B (zh) | 一种褐毛橐吾提取物在制备治疗白血病药物中的应用 | |
CN102416027B (zh) | 银杏活性成分萃取分离方法及萃取的活性物质在治疗心脑血管疾病药物中的应用 | |
Wei et al. | The immunomodulatory effects of active ingredients from Nigella sativa in RAW264. 7 cells through NF-κB/MAPK signaling pathways | |
CN104013636B (zh) | 瓦草五环三萜皂苷类化合物抗肿瘤的药物用途 | |
CN103610734B (zh) | 一种白花油麻藤提取物在制备治疗白血病药物中的应用 | |
CN103585211B (zh) | 阿莫尼亚脂提取物在制备治疗白血病药物中的应用 | |
CN103585193B (zh) | 通经草提取物在制备治疗白血病药物中的应用 | |
CN103585238B (zh) | 一种齿缘草提取物在制备治疗白血病药物中的应用 | |
CN103585220B (zh) | 毛莲菜提取物在制备治疗白血病药物中的应用 | |
CN105287487A (zh) | Solanoeclepin A在制备治疗白血病药物中的应用 | |
CN105521327B (zh) | 预防和/或治疗酒精性肝病或肝癌的药物组合物 | |
CN103585224B (zh) | 一种阿尔泰狗娃花提取物在制备治疗白血病药物中的应用 | |
CN105311148A (zh) | 一种中药提取物及其在制备治疗白血病中的应用 | |
CN105362664A (zh) | 一种中药组合提取物及其在制备治疗白血病中的应用 | |
CN107865884A (zh) | Orientin在制备治疗白血病药物中的应用 | |
CN105267277A (zh) | 一种滨紫草提取物在制备治疗白血病中的应用 | |
CN103463064B (zh) | Lycojaponicumin C在制备治疗白血病药物中的应用 | |
CN103463019B (zh) | Lycojaponicumin B在制备治疗白血病药物中的应用 | |
CN102872008B (zh) | Aphanamixoid A在治疗白血病药物中的应用 | |
CN103446134B (zh) | Lycojaponicumin A在制备治疗白血病药物中的应用 | |
CN104382927B (zh) | 罗勒多糖用作紫杉醇增效剂在制备抗肿瘤药物中的应用 | |
CN102872078B (zh) | Houttuynoid C在治疗白血病药物中的应用 | |
CN103405456B (zh) | Chukrasone A在制备治疗白血病药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN UNIVERSITY Free format text: FORMER OWNER: JINAN XINGYI MEDICAL TECHNOLOGY CO., LTD. Effective date: 20150716 |
|
C41 | Transfer of patent application or patent right or utility model | ||
C53 | Correction of patent for invention or patent application | ||
CB03 | Change of inventor or designer information |
Inventor after: Cheng Guanghui Inventor after: Mao Jincheng Inventor after: Wu Ning Inventor before: Kong Qianqian |
|
COR | Change of bibliographic data |
Free format text: CORRECT: INVENTOR; FROM: KONG QIANQIAN TO: CHENG GUANGHUI MAO JINCHENG WU NING |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20150716 Address after: 130012 Changchun Qianjin Street, Jilin, No. 2699 Applicant after: Jilin University Address before: 250101 No. 51 Industrial South Road, Ji'nan hi tech Zone, Shandong, Ji'nan Applicant before: Jinan Xingyi Medical Technology Co.,Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150812 Termination date: 20161031 |
|
CF01 | Termination of patent right due to non-payment of annual fee |